◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Bangkok Dusit Medical Services Public Company Limited (BDMS) Revenue 2021–2025

Name: Bangkok Dusit Medical Services Public Company Limited (BDMS) revenue history 2021-2025
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-19

Bangkok Dusit Medical Services Public Company Limited annual revenue for fiscal 2025 was THB 111.5 billion, an increase of 3.4% from THB 107.9 billion in fiscal 2024. All figures are reported results from public filings — no estimates or projections.

BDMS Annual Revenue

Revenue (annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Revenue	THB 111.5B	THB 107.9B	THB 100.9B	THB 91.9B	—

THB; THBM / THBB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BDMS Quarterly Revenue

Revenue (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Total Revenue	THB 26.9B	THB 28.2B	THB 28.5B	THB 28.2B	THB 26.7B	—

THB; THBM / THBB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Revenue at Comparable Companies

ASTERDM Revenue — Aster DM Quality Care Limited
MEDANTA Revenue — Global Health Limited
NH Revenue — Narayana Hrudayalaya Limited
KIMS Revenue — Krishna Institute of Medical Sciences Limited

More BDMS metrics: Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow

All BDMS financial statements → Interactive BDMS charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.